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Background: The impact of interventions on the progressive course of COPD is currently assessed by the slope of
the annual decline in FEV1 determined from serial measurements of the post-, in preference to the
pre-, bronchodilator FEV1. We therefore compared the yearly slope and the variability of the slope of the pre- versus
the post-bronchodilator FEV1 in men and women with mild to moderate COPD who participated in the 5-year
Lung Health Study (LHS).
Methods: Data were analyzed from 4484 of the 5887 LHS participants who had measurements of pre- and
post-bronchodilator FEV1 at baseline (screening visit 2) and all five annual visits. The annual rate of decline in FEV1
(±SE) measured pre- and post-bronchodilator from the first to the fifth annual visit was estimated separately using a
random coefficient model adjusted for relevant covariates. Analyses were performed separately within each of the
three randomized intervention groups. In addition, individual rates of decline in pre- and post-bronchodilator
FEV1 were also determined for each participant. Furthermore, sample sizes were estimated for determining
the significance of differences in slopes of decline between different interventions using pre- versus
post-bronchodilator measurements.
Results: Within each intervention group, mean adjusted and unadjusted slope estimates were slightly higher for
the pre- than the post-bronchodilator FEV1 (range of differences 2.6-5.2 ml/yr) and the standard errors around these
estimates were only minimally higher for the pre- versus the post-bronchodilator FEV1 (range 0.05-0.11 ml/yr).
Conversely, the standard deviations of the mean FEV1 determined at each annual visit were consistently slightly
higher (range of differences 0.011 to 0.035 L) for the post- compared to the pre-bronchodilator FEV1. Within each
group, the proportion of individual participants with a statistically significant slope was similar (varying by only
1.4 to 2.7%) comparing the estimates from the pre- versus the post-bronchodilator FEV1. However, sample size
estimates were slightly higher when the pre- compared to the post-bronchodilator value was used to determine
the significance of specified differences in slopes between interventions.* Correspondence: dtashkin@mednet.ucla.edu
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http://respiratory-research.com/content/13/1/70Conclusion: Serial measurements of the pre-bronchodilator FEV1 are generally sufficient for comparing the impact
of different interventions on the annual rate of change in FEV1.
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The annual rate of change in FEV1 has been measured
in numerous observational and interventional studies for
nearly half a century. In the seminal work of Fletcher
and Peto [1], on a cohort of 1136 smokers, an acceler-
ated annual rate of loss of FEV1 was observed in a subset
of smokers who were believed to be particularly vulner-
able to the injurious effects of cigarette smoking leading
to the development of chronic obstructive pulmonary
disease. This observation established an accelerated an-
nual loss of lung function as a characteristic feature of
COPD supporting subsequent definitions of COPD as a
progressive disease [2], although recent longitudinal data
suggest that COPD is not always progressive [3]. In the
aftermath of the Fletcher and Peto publication [1], longi-
tudinal population-based studies have examined the in-
fluence of both smoking and other exposures, such as
ambient air pollution, on lung function decline, mostly
using the FEV1 measured without bronchodilator admin-
istration [4-6]. Beginning with the first Lung Health
Study (LHS I), [7,8], the preferred method of determin-
ing the slope of decline in other interventional studies,
including trials of inhaled corticosteroids [9-12],
N-acetycysteine [13] and long-acting inhaled broncho-
dilators with or without inhaled corticosteroids [14,15],
has relied mainly on the post-bronchodilator FEV1
measurement.
The decision to use the slope of the post- as opposed
to the pre-bronchodilator FEV1 as the primary outcome
in LHS I was based, in part, on the assumption that
bronchodilator administration would reduce the influ-
ence of varying circadian and day-to-day bronchomotor
tone on the measurement of FEV1 [16-18], thereby redu-
cing the variability of the annual slope of FEV1 decline,
and potentially increasing the power of the study to
show a significant difference in the slope of decline in
FEV1 between the study groups. However, to date, it has
not been established that use of the post- compared to
the pre-bronchodilator FEV1 is associated with a lower
variance of the slope of annual change in FEV1 in
patients with COPD or that there is less month-to-
month variability than in the pre-bronchodilator mea-
surements. The objective of the present analysis was to
use data from LHS I participants to compare the
between-sessions variability of the pre- versus post-
bronchodilator FEV1 near the beginning of the studyand the variance of the annual slope of change in the
pre- versus post-bronchodilator FEV1 measured over five
years. If no difference in the variability of the slope of
annual change in FEV1 can be discerned between these
two methods of measuring the rate of change, then use
of only the pre-bronchodilator measurement would sim-
plify longitudinal studies of lung function change with-
out compromising the ability to detect possible
differences between different treatment regimens.Methods
Study population and FEV1 measurements
LHS I was a ten-center randomized clinical trial of 5,887
middle-aged smokers with the objective of determining
whether an intervention program combining intensive
smoking cessation counseling and an inhaled anticholin-
ergic bronchodilator could slow the rate of decline in
FEV1 over a five-year follow-up period during which
subjects underwent pre- and post-bronchodilator spir-
ometry annually [7,8]. Entry criteria included a history
of current regular smoking, ≥10 pack years of smoking,
age 35-60 yrs and the absence of other significant pul-
monary or other medical illness, as well as the presence
of mild to moderate airflow limitation (see below). A
history of asthma treated with regularly scheduled medi-
cation was also exclusionary. Potential subjects under-
went 3 separate screening visits (Figure 1). At the first
screening visit, spirometry was not rigidly controlled,
but spirometric methods used at the 2nd and 3rd screen-
ing visits and at all visits post-randomization were per-
formed using the same centrally supplied and certified
equipment and were rigorously standardized and moni-
tored to maintain suitable quality. At all of these spirom-
etry sessions, three acceptable and two repeatable
maneuvers were required from up to eight forced expira-
tions using LHS-specific standards for acceptability and
repeatability, as previously described [7,19], and the lar-
gest FEV1 and FVC values from acceptable and repeat-
able maneuvers were recorded. Bronchodilator response
to two inhalations of isoproterenol (200 μg) from a
metered-dose inhaler was determined at the 2nd screen-
ing visit and at all subsequent visits, except the 3rd
screening visit. At the latter visit, bronchoprovocation
with methacholine was performed, the details of which
have been published previously [20].
FEV1 /FVC  0.75 and
FEV1 50-90% predicted
Pre-bronchodilator 
FEV1 /FVC  0.70 and
FEV1 55-90 % predicted
Pre-methacholine 
FEV1 /FVC  0.75 and 
FEV1 50-90 % predicted
4 months after randomization
annual visits 1 –5 years after randomization
annual visits 1 –5 
years after 
randomization
Current smokers, age 35 – 60 
years, no history of regular use of
physician-prescribed 
bronchodilators
Screening Visit 1 
Spirometry* without 
bronchodilator 
Screening Visit 2 
Spirometry† (3 – 8 maneuvers) before
and after 2 inhalations of 
isoproterenol (100 µg / inh) 
Screening Visit 3 
Spirometry† (3 – 8 maneuvers) 
followed by methacholine 
challenge test
Eligible participants   
(N = 5887)  
randomly assigned to  
Smoking Intervention + Placebo
Inhaler (SIP)
(N = 1962)
Usual Care  
(N = 1962)
Smoking Intervention + Active
Bronchodilator Inhaler (SIA)
(N = 1962)
Spirometry† (3 – 8 maneuvers)
before and after 2 inhalations of
isoproterenol
Spirometry† (3 – 8 maneuvers) 
before and after 2 inhalations of 
isoproterenol
Spirometry† (3 – 8 maneuvers)
before and after 2 inhalations of
isoproterenol
Spirometry† (3 – 8 maneuvers) 
before and after 2 inhalations of 
isoproterenol
Spirometry† (3 – 8 maneuvers) 
before and after 2 inhalations of 
isoproterenol
* non-centralized spirometer   † centralized spirometer
Figure 1 Screening and post-randomization spirometry visits in the Lung Health Study.
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ratio of FEV1 to FVC of ≤0.70 and a pre-bronchodilator
FEV1 ≤90% predicted and ≥55% predicted [21] at the 2
nd
screening visit. The “pre-bronchodilator” measurement
was defined as the measurement obtained before the ad-
ministration of a short-acting bronchodilator [iso-
proterenol] as part of the study, as well as after an
adequate washout period following any prior use of
bronchodilator medication by participants. Eligible parti-
cipants were randomized in a 1:2 ratio to receive “usual
care” (UC) or “special intervention” (SI). The SI group
received a four-month intensive smoking cessationprogram followed by a five-year relapse prevention pro-
gram, along with physician advice and nicotine replace-
ment. In addition, participants in the SI group were
randomly assigned in a 1:1 ratio and in a double-blind
fashion to receive either placebo (SIP group) or ipratro-
pium bromide two inhalations, 18 μg per inhalation (SIA
group), which they were instructed to take three times
daily for the five-year duration of the study. The UC
group received only brief counseling on entry into the
study. All subjects were requested to return each year
for a total of five post-randomization annual visits dur-
ing each of which smoking status was determined (and
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ments of carbon monoxide) and spirometry was per-
formed both before and after isoproterenol using the
same methodology and rigorous standards as applied
during the 2nd and 3rd screening visit (Figure 1). In
addition, the SI group returned for a four-month post-
randomization visit that included pre- and post-
bronchodilator spirometry. Informed consent was
obtained from all participants at each of the ten LHS
clinical centers.
Written informed consent was obtained from all parti-
cipants originally enrolled in the LHS. The study was
approved by the institutional review boards of each of
the participating centers and was conducted in accord-
ance with the Declaration of Helsinki and Good Clinical
Practice guidelines.
Statistical analysis
Data from the LHS were reanalyzed to compare the an-
nual FEV1 decline measured pre- bronchodilator versus
post-bronchodilator for the three study groups (UC, SIP
and SIA), separately. Baseline characteristics for the
three treatment groups were summarized using descrip-
tive statistics. Among the 5887 subjects in the original
study, only the 4484 (~76%) who had measurements at
both baseline and all five annual follow-up visits were
included in this analysis. Demographic characteristics
and mean baseline FEV1 values were compared between
the included and excluded subgroups. For each included
treatment group, the annual rate of decline in FEV1
measured pre- and post- bronchodilator from the first to
the fifth annual visit was estimated separately using a
random coefficient model. Time (year), gender, age,
BMI, two-point methacholine concentration-FEV1
O’Connor slope [22] and baseline number of cigarettes
smoked per day were included in the model as fixed
effects; intercept and time (i.e., slope of FEV1) were ran-
dom effects. The two-point slope was computed as the
percent change in FEV1 at the highest delivered dose of
methacholine from the postdiluent control FEV1 divided
by the highest concentration of methacholine (in mg/ml)
that the subject received. Since, on average, either no
change or an increase in FEV1 was observed from base-
line to the first annual visit, followed by a linear decline
in FEV1 from annual visits 1 through 5 in the entire
LHS 1 population, for the present analysis all slopes
were calculated using data from the first through the
fifth annual visit. In addition, for each subject individu-
ally a linear regression model was used to obtain the an-
nual rate of decline in FEV1 for that subject from annual
visits 1 through 5. The number of subjects who had a
statistically significant individual annual rate of change
in FEV1 (p < 0.05) and the mean and standard deviation
of the slopes for those with and without a significantindividual rate of change were tabulated for pre- and
post- bronchodilator FEV1 separately within each of the
three treatment groups.
Based on the estimated slope (annualized change in
FEV1) and standard deviation determined for the three
parallel LHS treatment groups, we performed sample
size calculations to determine whether there are differ-
ences in the sample sizes needed to demonstrate a sig-
nificant difference in slopes of FEV1 decline between the
UC group and the SIP group, as well as between the UC
group and the SIA group, using the pre- versus the post-
bronchodilator FEV1. For these calculations, we assumed
equal sizes for each group, a normal distribution of the
annualized change in FEV1, a significance level of 0.05
(alpha) and 80% power (beta = 0.2) to detect the
observed difference in the annualized change in FEV1
between the two study groups in each pair (UC and SIP,
and UC and SIA) using a two-sided t-test. Sample sizes
were also calculated for the SIA and SIP groups versus a
hypothetical comparison study group with an assumed
slope difference of 10, 15 and 20 ml/yr, respectively, to
investigate possible differences in sample sizes using the
pre-bronchodilator vs. the post-bronchodilator FEV1 for
determining the slope.
All analyses were performed using SAS software.
Results
Average baseline characteristics for participants who
were included and excluded in the analysis are shown in
Table 1 for each study group. Baseline features were
modestly but significantly different between the included
and excluded participants for the following: in the SIA
group, excluded subjects were more often male and
non-Caucasian, had a slightly higher BMI and reported
smoking more cigarettes/day and a greater number of
pack-years; in the SIP group, excluded patients reported
smoking more cigarettes/day; and in the UC group,
excluded subjects had a lower FEV1. No significant dif-
ferences in baseline characteristics across the subjects in
the three treatment groups were noted, except for gen-
der and BMI. The SIA group had more females than the
SIP and UC groups (p = 0.009 and 0.006, respectively)
and the BMI was slightly lower in the SIA group than
the SIP and UC groups (p = 0.0077 and 0.0721, respect-
ively). The latter differences were very small and unlikely
to be clinically significant.
The linear slopes (mean and standard deviation) of the
pre- and post-bronchodilator FEV1 change from annual
visits 1 through 5 both unadjusted and adjusted (for age,
gender, cigarettes/day and log of the 2-point methacho-
line concentration-FEV1 response slope) are shown for
the UC, SIP and SIA groups separately in Table 2. The
mean values (± SD) of the pre- and post-bronchodilator
FEV1 at baseline and each annual visit are shown in
Table 1 Baseline characteristics of subjects included in versus excluded from the analysis
Included in this analysis Study Group
SIA SIP UC
No. of Subjects N 457 459 487
Y 1504 1503 1477
Subject Characteristics
Gender
% Male N 65.6 64.3 62.6
Y 59.3 63.9 64.2
p =0.0151 ns ns
Age, y
Mean± SD N 48.7 ± 7.1 48.3 ± 6.9 48.6 ± 7.0
Y 48.3 ± 6.8 48.6 ± 6.8 48.4 ± 6.8
ns ns ns
Race
% White N 92.8 94.8 95.3
Y 96.9 96.1 95.7
p =0.0001 ns ns
FEV1, L – pre (S2)
Mean± SD N 2.62 ± 0.61 2.62 ± 0.58 2.59 ± 0.57
Y 2.62 ± 0.61 2.65 ± 0.60 2.66 ± 0.60
ns ns p =0.0178
FEV1, L– post (S2)
Mean± SD N 2.73 ± 0.63 2.73 ± 0.60 2.70 ± 0.59
Y 2.73 ± 0.64 2.76 ± 0.63 2.78 ± 0.63
ns ns p =0.0155
BMI, kg/ht2
Mean± SD N 26.0 ± 4.1 25.7 ± 3.9 25.5 ± 4.1
Y 25.3 ± 3.9 25.7 ± 3.9 25.6 ± 3.9
p =0.002 ns ns
Cigarettes/Day
Mean± SD N 32.6 ± 13.4 32.8 ± 12.8 31.8 ± 12.6
Y 30.8 ± 13.1 31.1 ± 12.5 30.9 ± 12.9
p =0.006 p =0.007 ns
Pack/Years
Mean± SD N 42.6 ± 21.7 41.9 ± 19.9 41.7 ± 20.6
Y 39.8 ± 19.0 39.9 ± 18.5 40.2 ± 18.3
p =0.027 ns ns
O’Connor slope
Mean± SD N −14.4 ± 28.1 −12.2 ± 24.1 −12.6 ± 21.6
Y −13.2 ± 23.2 −12.0 ± 21.3 −12.9 ± 24.6
ns ns ns
SIA = Special Intervention Anticholinergic; SIP = Special Intervention Placebo; UC=Usual Care; S2 = second screening visit.
Differences for each measure between participants included versus not included in the analysis were tested using the t-test (for age, FEV1 and BMI), Chi-square
(for gender and race) and Wilcoxon rank sum test (for cigarettes/day, pack-years and O’Connor slope).
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ment for covariates, the mean slopes of both the pre-
and post-bronchodilator FEV1 are steeper by 12.2-15.5
ml/yr for the UC group compared to both SI groups
(Table 2), as previously reported for the post-bronchodilator slope in the entire LHS 1 population [7].
However, within each group, the mean unadjusted slope
estimates are only slightly higher for the pre- than the
post-bronchodilator FEV1 (range of differences 2.6-5.2
ml/yr) and the standard errors around these estimates
Table 2 Linear slope estimates (± SE) for the annual change (year 1-5) in pre- and post-bronchodilator FEV1 (ml/yr)
both unadjusted and adjusted for covariates (age, gender, cigarettes/day and log of the 2-point methacholine-FEV1
response slope) by intervention group
Group Unadjusted Adjusted
Slope Estimate ml/yr SE ml/yr p† Slope Estimate ml/yr SE ml/yr p†
UC (N= 1477)
Pre-bronchodilator −56.7 1.36 −56.7 1.37
Post-bronchodilator −52.8 1.25 −53.1 1.26
Difference* 3.9 1.07 <0.001 3.6 1.08 <0.001
SIP (N = 1503)
Pre-bronchodilator −43.2 1.30 −43.3 1.31
Post-bronchodilator −40.6 1.25 −40.8 1.27
Difference* 2.6 1.07 0.016 2.5 1.09 0.020
SIA (1504)
Pre-bronchodilator −42.7 1.36 −42.7 1.38
Post-bronchodilator −37.5 1.27 −37.6 1.29
Difference* 5.2 1.22 <0.001 5.1 1.24 <0.001
UC=Usual Care; SIP = Special Intervention Placebo; SIS = Special Intervention Anticholinergic.
*Difference between the linear slope estimates calculated using the pre- versus post-bronchodilator FEV1.
†p values refer to the significance of the differences between the slopes determined from the pre- versus post-bronchodilator FEV1 within each group
(mixed model).
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bronchodilator FEV1 (range 0.05-0.11 ml/yr). Similarly,
the mean adjusted slope estimates are slightly higher for
the pre- than the post-bronchodilator FEV1 in each
group (range of differences 2.5-5.1 ml/yr) and the stand-
ard errors around these estimates are only minimally
higher for the pre- vs. the post-bronchodilator FEV1
(range 0.04-0.11 ml/yr). The similarity of the slopes of
the pre- vs. post-bronchodilator FEV1 from annual visits
1 through 5 is readily discerned by inspection of curves
drawn for the mean values of the pre- vs. post-
bronchodilator FEV1 at each annual visit over this time
period (Figure 2). Moreover, the standard deviations of
the mean FEV1 at each of these time points are very
similar on comparison of the pre- and post-
bronchodilator values (Additional file 1).
Table 3 shows the percentage of participants in each
randomized group who exhibited a statistically signifi-
cant individual slope of pre- and post-bronchodilator
FEV1 change over annual visits 1 through 5. Within each
group, the percentage of individual participants with a
statistically significant slope was similar between the
slopes estimated from the pre- versus the post-
bronchodilator FEV1, the differences varying by only 1.4-
2.7%. The percentage of UC participants who exhibited
a statistically significant slope of both pre- and post-
bronchodilator FEV1 decline (40.2 and 38.7%, respect-
ively) was significantly higher than the percentage of
participants in each SI group (range 25.4-30.5%) who
demonstrated a statistically significant slope, most likely
attributable to the generally steeper significant slopes in
the UC group (range of means 53.5-56.7 ml/yr) than inthe two SI groups (range of means 37.5-43.2 ml/yr) as a
consequence of the significantly higher rates for sus-
tained quitting in the SI groups than the UC group (7).
The differences of the pre- and post-bronchodilator
FEV1 in the SIP group between screening visit 2 and
month 4 reflect the month-to-month variability in FEV1
unconfounded by the introduction of maintenance treat-
ment with a bronchodilator (Additional file 2). The
mean difference in pre-bronchodilator FEV1 from
screening visit 2 to month 4 is actually smaller than that
for the post-bronchodilator measurements, although the
variances are similar.
Using the pre- and post-bronchodilator FEV1, the
sample sizes required 1) to demonstrate significant dif-
ferences between the UC vs. SIA group and the UC vs.
SIP group are shown in Table 4 and 2) to demonstrate a
significant slope difference of 10, 15 and 20 ml/yr for
the SIA and the SIP groups vs. the hypothetical compari-
son group are shown in Table 5. A smaller N was
required to show a difference between the SIP and the
UC group using the pre-bronchodilator compared to the
post-bronchodilator FEV1, while, conversely, a larger N
was needed to show a difference between the SIA and
UC groups using the pre- compared to the post-BD
FEV1 (Table 4). These differences in sample size esti-
mates comparing the UC group with each of the SI
groups are related to the differences in the means of the
slopes (effect size) between the groups, as well as the dif-
ferences in the SD shown in Table 2. On the other hand,
comparison of the sample sizes needed to show statis-
tical significance for specified differences in slope be-
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Figure 2 Mean values of pre- and post-bronchodilator FEV1 at
screening visit 2 and annual visits 1 through 5 in A) UC group,
B) SIP group and C) SIA group.
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that slightly larger numbers of subjects would be
required using pre- than post-bronchodilator FEV1 mea-
surements, especially for relatively small hypothetical
differences in slope (Table 5).Discussion
We found that, for the UC and the two SI groups, both
the mean slope and the variance of the slope of the an-
nual change in the pre-bronchodilator FEV1 were fairly
similar to the slope and variance of the slope determined
using the post-bronchodilator FEV1 (Table 2), suggesting
that the post-bronchodilator measurement offered little
advantage over the pre-bronchodilator FEV1 for tracking
the course of COPD in LHS participants. These findings
are consistent with our observation of comparable
between-month variability of the pre- and the post-
bronchodilator FEV1 in the SIP group (Additional file 1).
Our results indicating that the variability of the slope
of annual change in FEV1 is not substantially reduced by
determining the slope based on the post-bronchodilator
compared to the pre-bronchodilator FEV1 are further
supported by the observation that, within each group,
the proportion of participants with a statistically signifi-
cant individual slope of decline in the post-
bronchodilator FEV1 was similar to the proportion with
a statistically significant individual slope determined
from the pre-bronchodilator FEV1 since the statistical
significance of the individual slope of FEV1 decline is
influenced, in large part, by the variance of the slope.
On the other hand, any possible advantage, with re-
spect to savings in time and effort, of restricting the
measurement of FEV1 to only the pre-bronchodilator
value for studies of the impact of an intervention on the
annual rate of change in FEV1 must be balanced by the
comparative size of the sample required, with adequate
power, to show a significant difference between the
interventions. The sample size is driven by both the ef-
fect size and the variance of the annual slope. Therefore,
we determined the sample sizes needed to show a sig-
nificant difference between the UC group and each of
the SI groups, as well as to show significant specified dif-
ferences (10, 15 and 20 ml/yr) between each of the SI
groups and a hypothetical comparison group. Inconsist-
ent differences in the required sample size were shown
for determining significant differences between the UC
group and each of the SI groups using pre- vs. post-
bronchodilator data (Table 4). However, in general, a
modestly larger sample size was required to demonstrate
significance for specified differences in slope between a
hypothetical comparison group and each SI group, par-
ticularly for relatively small assumed differences in slope
(Table 5), thus potentially incurring an additional cost
Table 3 Proportion of participants (95% CI) in each intervention group with a statistically significant individual annual
rate of change in pre- versus post-bronchodilator FEV1 from annual visit 1 through 5
Intervention Group Proportion with significant change in FEV1 (95% CI)
Pre-bronchodilator FEV1 Post-bronchodilator FEV1
UC 40.1 (37.6-42.6) 38.7 (36.2-41.2)
SIP 27.8 (25.6-30.1) 30.5 (28.1-32.8)
SIA 27.0 (24.7-29.2) 25.4 (23.3-27.6)
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the pre-bronchodilator FEV1 were measured.
In studies conducted over approximately the last 25
years comparing the impact of different therapeutic inter-
ventions in COPD on the progression of the disease, it
became common practice to use the post-bronchodilator,
rather than the pre-bronchodilator, FEV1 for calculating
the annual rate of change as the primary measure of the
course of the disease [7,9-15]. The rationale for this prac-
tice, is likely to have been based on the belief that the
post-bronchodilator value better “standardizes” the FEV1
than the pre-bronchodilator value, since the pre-
bronchodilator value could be affected by day-to-day and
within-day variability in bronchomotor tone, as well as by
residual bronchodilation from the last dose of either res-
cue or maintenance bronchodilator medication if an ad-
equate washout period was not observed. The goal of this
“standardization” would be to reduce the variability of
the FEV1 and thus better estimate the slope of the annual
change in FEV1, thereby decreasing the sample size
required to demonstrate a significant difference in slope
between therapeutic interventions.
On the other hand, serial spirometry studies evaluating
the time course of FEV1 over 24 hrs have failed to show
any difference in the circadian pattern of FEV1 compar-
ing responses to placebo with those to bronchodilator
medication [23,24]. Moreover, the short-term response
to a bronchodilator is influenced by several factors [25]
in consequence of which the post-bronchodilator incre-
ment in FEV1 is itself highly variable both within and be-
tween patients with COPD [26,27]. One of the factorsTable 4 Estimates of sample sizes (N) per group required
to demonstrate (A) significant slope differences between
the UC vs., separately, the SIA and SIP group using the
pre- vs. post-bronchodilator FEV1 and (B) significant
slope differences of 10, 15 and 20 ml/yr for the SIA and
the SIP group, separately, vs. a hypothetical comparison
group using pre- and post-bronchodilator FEV1,
respectively
SIA vs. UC SIP vs. UC
Using pre-bronchodilator data 221 227
Using post-bronchodilator data 160 248affecting the acute response to a bronchodilator mea-
sured in terms of the absolute improvement in FEV1 is
the pre-bronchodilator FEV1 % predicted, such that,
across the spectrum of GOLD stages of severity from
moderate to very severe, the magnitude of the FEV1 re-
sponse has been observed to be largest in patients with
moderate COPD and smallest in patients with very se-
vere COPD [28,29]. Consequently, as COPD progresses
from moderate to very severe airflow obstruction over
time, one would expect a progressively smaller absolute
increment in FEV1 after bronchodilator administration,
which could influence the annual slope of decline in the
post-bronchodilator FEV1. In contrast, patients with
relatively mild airflow obstruction, as observed on the
baseline visit of the LHS, exhibit a minimal response to
a bronchodilator [7,30], in contrast to the much greater
response in patients with moderate to severe airflow ob-
struction, possibly due to the effect of Poisseuille’s Law
[31]. Consequently, when such patients progress to a
greater degree of airflow obstruction, one would expect
a relatively larger acute response to a bronchodilator, as
was demonstrated in the continuing and intermittent
smokers over the 11 years of follow-up in the LHS [30].
Whether because of these or other factors, the yearly
slope of FEV1 and the variance of this slope do, in fact,
differ between the pre- vs. the post-bronchodilator FEV1
has heretofore not been specifically addressed.
This study has several strengths as well as weaknesses.
The major strength is the exceptional rigor with which
the centralized spirometry assessments were performed
and continually monitored for quality control [19], thus
minimizing variability due to technical factors. Other
strengths include the large number of subjects studied
(nearly 6,000, over three-quarters of whom completed
all annual visits) and the relatively high representation of
females (35%) compared to most other interventional
studies in COPD. A weakness is the somewhat limited
spectrum of COPD represented by the subjects, all of
whom had only mild to moderate airflow obstruction at
entry into the study and generally had not been pre-
scribed maintenance bronchodilator or other medication
for their COPD, so that our findings might not apply to
patients with severe or very severe COPD nor to non-
smokers and those without COPD. Similarly, the average
Table 5 Estimates of sample sizes (N) per group required to demonstrate (A) significant slope differences between the
UC vs., separately, the SIA and SIP group using the pre- vs. post-bronchodilator FEV1 and (B) significant slope
differences of 10, 15 and 20 ml/yr for the SIA and the SIP group, separately, vs. a hypothetical comparison group
using pre- and post-bronchodilator FEV1, respectively
Difference of Slope Using pre-BD data Using post-BD data
SIA vs. comparison group 10 435 382
15 194 171
20 110 97
SIP vs. comparison group 10 398 371
15 178 166
20 101 94
Tashkin et al. Respiratory Research 2012, 13:70 Page 9 of 10
http://respiratory-research.com/content/13/1/70age of the participants (~48 yrs) was much lower than
that of COPD patients participating in pharmacothera-
peutic trials. The imbalance in some of the baseline
characteristics between the ~76% of participants
included in the analysis and the remainder who were
excluded might be another limitation. To address this
limitation, we re-analyzed the data to determine the esti-
mated annual change in FEV1 in the total LHS popula-
tion of 5,887 participants using multiple imputation of
the missing data (see Additional file 3). The results of
this analysis yielded differences between the mean slopes
and slope variances determined from the pre- versus the
post-bronchodilator FEV1 that were very similar to those
found when the analysis was restricted only to those
who completed all annual visits. Another limitation is
that COPD was defined by a pre-bronchodilator ratio of
FEV1 to FVC of <70%, rather than the currently recom-
mended post-bronchodilator ratio [2]. Consequently,
some subjects with fully reversible airflow obstruction
were included in the study. There were 503 subjects
whose post-bronchodilator FEV1 % predicted was 90%
or greater, and 1246 whose post-bronchodilator FEV1/
FVC % was 70% or greater. On the other hand, subjects
who were receiving regularly prescribed medication for
asthma were excluded.
We conclude that serial measurements of the pre-
bronchodilator FEV1 appear to be adequate for compar-
ing the impact of different interventions on the annual
rate of change in FEV1, thus simplifying the design of
such longitudinal studies. On the other hand, relying
only on the pre-bronchodilator measurement might re-
quire a slightly larger sample size to show significant dif-
ferences between interventions, particularly if relatively
small differences in slope are observed. Moreover, meas-
urement of the response to a bronchodilator is import-
ant at baseline to exclude the presence of fully reversible
airflow obstruction and, in addition, to describe the de-
gree of partial reversibility for descriptive and potential
analytic purposes, although the pre-bronchodilator FEV1
has been found to be just as accurate as the post-
bronchodilator measurement in predicting mortality inthe LHS [32]. In addition, if only the pre-bronchodilator
measurement is performed over time, care should be
taken to ensure that subjects withhold their concomitant
bronchodilator medication for a suitable washout period
prior to spirometry testing. Furthermore, whether or not
post-bronchodilator measurements are also performed,
subjects should be studied at approximately the same
time of day to minimize variability due to the influence
of circadian rhythm.Additional files
Additional file 1: Mean (±SD) pre- and post-bronchodilator FEV1 at
baseline and each annual visit by intervention group.
Additional file 2: Mean values ± SD of pre- and post-
bronchodilator FEV1 at the 2
nd screening visit (S2) and the 4 month
visit (M4) and the mean M4-S2 differences ± SD in SIP participants
(N=1427).
Additional file 3: Estimates of annual change in FEV1 (in liters)
using multiple imputation of missing data in the entire LHS
population*.
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